<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132324</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 59872-102</org_study_id>
    <nct_id>NCT03132324</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease</brief_title>
  <official_title>A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety and tolerability, and the
      pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell
    Disease indication.
  </why_stopped>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">October 3, 2018</completion_date>
  <primary_completion_date type="Actual">October 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of INCB059872 assessed by monitoring frequency, duration, and severity of adverse events</measure>
    <time_frame>Screening through 35 days after end of treatment, up to approximately 3 months per participant.</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fetal hemoglobin (HbF) from baseline</measure>
    <time_frame>Baseline through 2 weeks after end of treatment, up to approximately 2.5 months per participant.</time_frame>
    <description>Pharmacodynamic activity assessed by measuring changes of HbF from baseline and their correlation to INCB059872 treatment. The HbF (F cells) in human whole blood will be characterized using flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of INCB059872</measure>
    <time_frame>Baseline to Day 28.</time_frame>
    <description>Defined as maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of INCB059872</measure>
    <time_frame>Baseline to Day 28.</time_frame>
    <description>Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>INCB059872 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB059872 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB059872 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB059872</intervention_name>
    <description>INCB059872 tablets</description>
    <arm_group_label>INCB059872 0.5 mg</arm_group_label>
    <arm_group_label>INCB059872 1 mg</arm_group_label>
    <arm_group_label>INCB059872 2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of SCD (sickle cell SS) confirmed through hemoglobin electrophoresis.

          -  Must be red blood cell (RBC) transfusion-independent (not currently on regularly
             scheduled transfusions) for ≥ 3 months from the time of first dose of study drug.

          -  No RBC transfusion within 30 days of first dose of study drug.

          -  Hydroxyurea (HU) refractory

             -Must not have received HU therapy during the 3 months before receiving study drug.

          -  Creatinine clearance ≥ 60 mL/min based on the institutional formula.

          -  Willingness to avoid pregnancy or fathering children.

        Exclusion Criteria:

          -  Any unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic
             toxicities not expected to resolve.

          -  Pregnant or nursing women or participants expecting to conceive or father children
             within the projected duration of the study, starting with screening visit through
             completion of safety follow-up.

          -  Received an investigational study drug within 28 days or 5 half-lives (whichever is
             longer) before receiving the first dose of study drug (requirement may be waived with
             medical monitor approval).

          -  Chronic or current active infectious disease requiring systemic antibiotics,
             antifungal, or antiviral treatment.

          -  Prior receipt of LSD1 inhibitor therapy for any indication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fitzroy Dawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Health and Medical Center</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Centers of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle cell disease (SCD)</keyword>
  <keyword>sickle cell SS</keyword>
  <keyword>lysine demethylase 1 (LSD1) inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

